JRCT ID: jRCT2001200001
Registered date:13/10/2020
Special use results survey for interstitial lung disease of ENHERTU FOR INTRAVENOUS DRIP INFUSION 100mg-gastric cancer-
Basic Information
| Recruitment status | Not Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | unresectable advanced / recurrent gastric cancer |
| Date of first enrollment | 25/09/2020 |
| Target sample size | 900 |
| Countries of recruitment | |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | ILD expression based on the judgement result of ILD outside judgment Committee |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | All patients with unresectable advanced / recurrent gastric cancer who start administration of this drug within the enrollment period |
| Exclude criteria | NONE |
Related Information
| Primary Sponsor | Tanabe Hirokazu |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | GPSP for Contact |
| Address | 3-5-1,NihonbashiHoncho,Chuo-ku,Tokyo Tokyo Japan 103-8426 |
| Telephone | +81-3-6225-1059 |
| contact_gpsp@daiichisankyo.co.jp | |
| Affiliation | DAIICHI SANKYO Co.,Ltd. |
| Scientific contact | |
| Name | Hirokazu Tanabe |
| Address | 3-5-1,NihonbashiHoncho,Chuo-ku,Tokyo Tokyo Japan 103-8426 |
| Telephone | +81-3-6225-1059 |
| contact_gpsp@daiichisankyo.co.jp | |
| Affiliation | DAIICHI SANKYO Co.,Ltd. |